Programmed cell death-1 inhibition in lymphoma.
Cancers can evade the host immune system by inducing upregulation of immune inhibitory signals. Anti-programmed cell death-1 (PD-1) monoclonal antibodies block these inhibitory signals allowing the host to mount an immune response against malignant cells. This class of drugs is active in solid tumours, where upregulation of cell-surface PD-1 ligand proteins is nearly uniform. Because lymphoma is a malignancy of immune system cells, the role of the PD-1 pathway in these neoplasms is more complex. However, early clinical trials using PD-1 inhibitors have shown significant clinical activity in various subtypes of relapsed lymphoma. In this Review, we assess the scientific literature on the role of the PD-1 pathway in lymphoma, the relevant clinical data for PD-1 inhibition, and future strategies for this next generation of anticancer agents.
Department of Medical Oncology and Clinical Haematology, Olivia Newton John Cancer and Wellness Centre, Austin Hospital, Melbourne, VIC, Australia; Department of Medical Oncology, Eastern Health, Melbourne, VIC Australia; Monash University, Melbourne, VIC, Australia. Electronic address: eliza.hawkes@onjcri.org.au.
Eliza A
EA
Hawkes
Department of Medical Oncology and Clinical Haematology, Olivia Newton John Cancer and Wellness Centre, Austin Hospital, Melbourne, VIC, Australia; University of Melbourne, Melbourne, VIC, Australia.
Andrew
A
Grigg
Department of Medical Oncology and Clinical Haematology, Olivia Newton John Cancer and Wellness Centre, Austin Hospital, Melbourne, VIC, Australia; Department of Oncology, Northern Hospital, Melbourne, VIC, Australia; Department of Medical Oncology, Ballarat Health Services, Ballarat, VIC, Australia.
Geoff
G
Chong
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008024:Ligands; D008223:Lymphoma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D058990:Molecular Targeted Therapy; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors* / Q000276:immunology; D015398:Signal Transduction / Q000235:genetics
D000911:Antibodies, Monoclonal; D008024:Ligands; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor